Tandem transplants with different high-dose regimens improve the complete remission rates in XXXX . Results of a Grupo Espa  ol de S  ndromes Linfoproliferativos/Trasplante Aut  logo de M  dula Osea phase II trial.

@entity1 @entity13462 @entity3012 @entity786 @entity19498 @entity1582 @entity3601 @entity2879 @entity3600
Between 1994 and 1999, 88 @entity1582 ( @entity1582 ) @entity1 were included in a phase II study to evaluate a tandem autologous stem cell transplantation (ASCT) programme. The first was conditioned with @entity3601 200 mg/m2 (MEL200- @entity19498 ), and the second with @entity786 , @entity2879 and @entity3600 (CBV- @entity13462 ). All @entity1 were in response after MEL200- @entity19498 . A control group of @entity1582 @entity1 with response to a single ASCT was selected to compare outcomes. After MEL200- @entity19498 , 26 @entity1 (30%) achieved complete remission (CR). Of the remaining 48 evaluable @entity1 , 16 (33%) achieved CR with CBV- @entity13462 . The final CR rate was 48%. The 5-year survival ( @entity3012 ) was 55%[95% confidence interval (CI) 43-67%] while the event-free survival (EFS) was 28% (95% CI 15-39%). CR status after CBV- @entity13462 was the most important prognostic factor for @entity3012 and EFS (P = 0.00001), although no differences in outcomes were detected when the @entity1 in CR after MEL200- @entity19498 were compared with those who obtained CR after CBV- @entity13462 . Univariate and multivariate analyses showed improved @entity3012 and EFS for the tandem series as compared with the control series treated with a single MEL200-ASCT. However, in a stratified comparison by response, there were no prognostic differences between tandem @entity1 and control @entity1 treated with a single ASCT. In summary, our study suggests that the benefit of a second high-dose therapy course depends on its capacity to result in CR for @entity1582 @entity1 who have not attained CR after @entity19498 .
